Validation of Digital Heart Rhythm Devices in the Detection of Atrial Fibrillation (VALIDATION)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Henri M.P.B.C. Gruwez, MD
- Phone Number: +32475223949
- Email: henri.gruwez@zol.be
Study Locations
-
-
Limburg
-
Genk, Limburg, Belgium, 3600
- Ziekenhuis Oost-Limburg
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- The patient is an ambulatory cardiology patient.
- The patient is at least 18 years old.
- The patient is sinus or in atrial fibrillation.
- The patient is able to perform the study procedures together with the study assistant.
Exclusion Criteria:
- Patients with a pacemaker
- Inclusion in another clinical trial that may influence the results of this trial
- The patient is unable to comprehend the informed consent.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Other: Study population (single arm)
|
The sequence of the digital heart rhythm measurements is randomly assigned for each patient.
The reference heart rhythm is determined by a simultaneous recording with a 12-lead ECG as gold standard.
The sequence of the digital heart rhythm measurements is randomly assigned for each patient.
The reference heart rhythm is determined by a simultaneous recording with a 12-lead ECG as gold standard.
The sequence of the digital heart rhythm measurements is randomly assigned for each patient.
The reference heart rhythm is determined by a simultaneous recording with a 12-lead ECG as gold standard.
The sequence of the digital heart rhythm measurements is randomly assigned for each patient.
The reference heart rhythm is determined by a simultaneous recording with a 12-lead ECG as gold standard.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Sensitivity
Time Frame: During the heart rhythm measurements
|
Proportion of true positives tests with the device of interest out of all patients with AF on the 12-lead ECG.
|
During the heart rhythm measurements
|
|
Specificity
Time Frame: During the heart rhythm measurements
|
Proportion of true negative tests with the device of interest out of all patients in sinus rhythm on the 12-lead ECG.
|
During the heart rhythm measurements
|
|
Accuracy
Time Frame: During the heart rhythm measurements
|
Proportion of correct classifications with the device of interest.
Correct classification is provided by the 12-lead ECG.
|
During the heart rhythm measurements
|
|
Cramer's V
Time Frame: During the heart rhythm measurements
|
The association of between the classification by the device of interest versus the 12-lead ECG, expressed as Cramer's V.
|
During the heart rhythm measurements
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Patient preference score (for the use of the diagnostic devices)
Time Frame: During the heart rhythm measurements
|
This score is a (1-5) ordinal result based on the VALIDATION study questionnaire.
|
During the heart rhythm measurements
|
|
Positive predictive value
Time Frame: During the heart rhythm measurements
|
Proportion of true positive tests out of all positive tests.
|
During the heart rhythm measurements
|
|
Negative predictive value
Time Frame: During the heart rhythm measurements
|
Proportion of true negative tests out of all negative tests.
|
During the heart rhythm measurements
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Sensitivity, specificity and Cramer's V using only measurements of sufficient quality for analysis
Time Frame: During the heart rhythm measurements
|
The proportion of true positive tests, true negative tests and the association of between the classification of the test devices and 12-lead ECG.
|
During the heart rhythm measurements
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Estimated)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- Z-2023023
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.